Schedule of net loss attributable to non-controlling interest |
| | BioCorRx Pharmaceuticals, Inc. | | | Joseph DeSanto MD | | Net loss | | $ | (106,233 | ) | | $ | 244 | | Average Non-controlling interest percentage of profit/losses | | | 24.2 | % | | | 35.0 | % | Net loss attributable to the non-controlling interest | | $ | (25,708 | ) | | $ | 85 | |
| | BioCorRx Pharmaceuticals, Inc. | | | Joseph DeSanto MD | | Net loss | | $ | (2,397 | ) | | $ | (1,395 | ) | Average Non-controlling interest percentage of profit/losses | | | 24.2 | % | | | 35.0 | % | Net loss attributable to the non-controlling interest | | $ | (580 | ) | | $ | (488 | ) |
| | BioCorRx Pharmaceuticals, Inc. | | | Joseph DeSanto MD | | Net loss | | $ | (175,033 | ) | | $ | (1,720 | ) | Average Non-controlling interest percentage of profit/losses | | | 24.2 | % | | | 35.0 | % | Net loss attributable to the non-controlling interest | | $ | (42,358 | ) | | $ | (602 | ) |
| | BioCorRx Pharmaceuticals, Inc. | | | Joseph DeSanto MD | | Net loss | | $ | (5,692 | ) | | $ | (4,945 | ) | Average Non-controlling interest percentage of profit/losses | | | 24.2 | % | | | 35.0 | % | Net loss attributable to the non-controlling interest | | $ | (1,378 | ) | | $ | (1,730 | ) |
|
Schedule of changes in non controlling interest |
Balance, December 31, 2023 | | $ | (128,834 | ) | Net loss attributable to the non-controlling interest | | | (42,960 | ) | Balance, September 30, 2024 | | | (171,794 | ) |
Balance, December 31, 2022 | | $ | (125,257 | ) | Net loss attributable to the non-controlling interest | | | (3,108 | ) | Balance, September 30, 2023 | | | (128,365 | ) |
|